What is the share price of Dishman Carbogen Amcis Ltd (DCAL) today?
The share price of DCAL as on 15th July 2025 is ₹256.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dishman Carbogen Amcis Ltd (DCAL) share?
The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are- Past 1 week: -7.29%
- Past 1 month: -10.11%
- Past 3 months: 22.17%
- Past 6 months: 0.53%
- Past 1 year: 52.83%
- Past 3 years: 112.96%
- Past 5 years: 62.28%
What are the peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL)?
The peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL) include:What is the market cap of Dishman Carbogen Amcis Ltd (DCAL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹3915.66 Cr as of 15th July 2025.What is the 52 week high and low of Dishman Carbogen Amcis Ltd (DCAL) share?
The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹307.98 and the 52-week low is ₹155.05.What is the PE and PB ratio of Dishman Carbogen Amcis Ltd (DCAL) stock?
The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is 1208.54. The P/B (price-to-book) ratio is 0.70.Which sector does Dishman Carbogen Amcis Ltd (DCAL) belong to?
Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Dishman Carbogen Amcis Ltd (DCAL) shares?
You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dishman Carbogen Amcis Ltd
DCAL Share Price
256.402.66% (+6.65)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DCAL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
DCAL Performance & Key Metrics
DCAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 1,208.54 | 0.70 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.80% |
DCAL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
DCAL Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
DIVISLAB
PE Ratio
82.13
82.13
1Y Return
48.40%
48.40%
Buy Reco %
50.00
50.00
SYNGENE
PE Ratio
51.52
51.52
1Y Return
11.98%
11.98%
Buy Reco %
71.43
71.43
AARTIPHARM
PE Ratio
31.04
31.04
1Y Return
55.67%
55.67%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
29.77
29.77
1Y Return
80.96%
80.96%
Buy Reco %
0.00
0.00
BROOKS
PE Ratio
-45.70
-45.70
1Y Return
91.50%
91.50%
Buy Reco %
0.00
0.00
DCAL Sentiment Analysis
DCAL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DCAL Stock Summary · May 2025
The company demonstrated robust financial performance, achieving a 9.4% revenue increase and significant EBITDA growth, driven by effective cost management and operational efficiencies. With a strong development pipeline and successful operational advancements, particularly in France and China, the firm is well-positioned for future growth, despite facing challenges such as rising raw material costs and currency fluctuations. Strategic investments in digital transformation and enhanced collaboration across regions are expected to bolster profitability and operational effectiveness. While navigating project viability concerns and increasing trade receivables, management remains optimistic about maintaining strong client relationships and achieving ambitious targets for revenue and return on capital employed. Overall, the outlook reflects a balanced approach to growth and financial health.
DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
8Strong Financial Performance
The company reported significant financial achievements, including a 9.4% increase in revenue from operations for
Operational Advancements and Capacity Expansion
The company achieved operational milestones, particularly with its French facility, which is now fully operational
DCAL Stock Challenges
DCAL Stock Challenges
7Declining Revenue in Specific Segments
The Cholesterol and Vitamin D analogues business reported a decrease in revenue, generating INR 305
High Inventory Levels
The company reported high inventory days ranging from 550 to 650 days, attributed to the
DCAL Forecast
DCAL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
DCAL
DCAL
Income
Balance Sheet
Cash Flow
Annual Normal View
DCAL Income Statement
DCAL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,739.82 | 1,740.48 | 2,112.42 | 2,088.06 | 1,950.48 | 2,184.11 | 2,440.69 | 2,643.98 | 2,733.18 | 2,735.22 | ||||||||||
Raw Materials | 329.58 | 402.19 | 378.01 | 476.38 | 434.77 | 460.50 | 630.40 | 601.21 | 2,260.67 | 2,262.71 | ||||||||||
| Power & Fuel Cost | 49.47 | 48.33 | 56.14 | 60.26 | 41.87 | 62.73 | 87.83 | 104.31 | ||||||||||||
| Employee Cost | 596.02 | 625.40 | 714.64 | 762.27 | 872.91 | 981.49 | 1,029.86 | 1,208.16 | ||||||||||||
| Selling & Administrative Expenses | 147.69 | 136.29 | 190.73 | 124.58 | 113.81 | 147.71 | 197.66 | 205.53 | ||||||||||||
| Operating & Other expenses | 138.47 | 37.23 | 167.18 | 122.55 | 196.60 | 171.53 | 183.12 | 216.20 | ||||||||||||
EBITDA | 478.59 | 491.04 | 605.72 | 542.02 | 290.52 | 360.15 | 311.82 | 308.57 | 472.51 | 472.51 | ||||||||||
| Depreciation/Amortization | 213.50 | 211.42 | 240.38 | 282.87 | 307.94 | 307.59 | 280.72 | 310.86 | 293.74 | 293.74 | ||||||||||
| PBIT | 265.09 | 279.62 | 365.34 | 259.15 | -17.42 | 52.56 | 31.10 | -2.29 | 178.77 | 178.77 | ||||||||||
| Interest & Other Items | 49.01 | 48.83 | 56.55 | 61.95 | 47.61 | 56.81 | 85.69 | 119.97 | 159.46 | 159.46 | ||||||||||
| PBT | 216.08 | 230.79 | 308.79 | 197.20 | -65.03 | -4.25 | -54.59 | -122.26 | 19.31 | 19.31 | ||||||||||
| Taxes & Other Items | 70.65 | 76.22 | 98.46 | 38.69 | 100.10 | -22.26 | -24.79 | 31.19 | 16.07 | 16.07 | ||||||||||
| Net Income | 145.43 | 154.57 | 210.33 | 158.51 | -165.13 | 18.01 | -29.80 | -153.45 | 3.24 | 3.24 | ||||||||||
| EPS | — | 19.15 | 13.03 | 9.96 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 0.21 | ||||||||||
| DPS | 1.20 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DCAL Company Updates
FY 2025FY 2025
Investor Presentation
May 22PDF
Feb 12PDF
Nov 13PDF
DCAL Stock Peers
DCAL Past Performance & Peer Comparison
DCAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation-basic on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | 1,208.54 | 0.70 | — |
| Divi's Laboratories Ltd | 82.13 | 13.26 | 0.44% |
| Syngene International Ltd | 51.52 | 5.41 | 0.20% |
| Aarti Pharmalabs Ltd | 31.04 | 4.81 | 0.54% |
DCAL Stock Price Comparison
Compare DCAL with any stock or ETFCompare DCAL with any stock or ETF
DCAL
DCAL Holdings
DCAL Shareholdings
DCAL Promoter Holdings Trend
DCAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DCAL Institutional Holdings Trend
DCAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DCAL Shareholding Pattern
DCAL Shareholding Pattern
DCAL Shareholding History
DCAL Shareholding History
Foreign Institutions
Mutual Funds Invested in DCAL
Mutual Funds Invested in DCAL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9460% | Percentage of the fund’s portfolio invested in the stock 0.72% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/89 (-32) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1317% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 205/255 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 463/755 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing DCAL stock
smallcases containing DCAL stock
Looks like this stock is not in any smallcase yet.
DCAL Events
DCAL Events
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
DCAL Upcoming Dividends
DCAL Upcoming Dividends
No upcoming dividends are available
DCAL Past Dividends
DCAL Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
DCAL Stock News & Opinions
DCAL Stock News & Opinions
Articles & Videos
Spotlight
Dishman Carbogen Amcis' Ahmedabad facility clears USFDA inspection without observations
The inspection was conducted from 9 June to 13 June 2025. According to the company's statement, the audit concluded without any observations or the issuance of a Form 483, indicating that the USFDA found no procedural or compliance-related concerns during the inspection. As a result, the company's facilities at Naroda and Bavla in India, along with multiple group facilities in Switzerland and the Netherlands, continue to maintain USFDA approval. The official announcement was made on Saturday, 14 June 2025. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. The company reported a consolidated net profit of Rs 43.09 crore in Q4 March 2025 as against a net loss of Rs 69.92 crore in Q4 March 2024. Revenue from operations rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. The counter declined 2.29% to Rs 273.05 on the BSE. Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: ' Aarau site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. ' Neuland site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Dishman Carbogen spurts after turnaround Q4 outcome
Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-tax profit before exxceptional items stood at Rs 39.45 crore in Q4 FY25 as against pre-tax loss before exceptional items of Rs 46.11 crore in Q4 FY24. For the full year, the company reported net profit of Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore in the year ended March 2024. Net sales rose 3.66% YoY to Rs 2711.50 crore in the year ended March 2025. Pre-tax profit before exceptional items stood at Rs 37.42 crore in FY25 as against pre-tax loss before exceptional items of Rs 116.12 crore in FY24. During the quarter and year ended 31 March 2025, certain subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairment were Rs 0.77 crore and Rs 7.13 crore respectively for the quarter and year. Further, during the quarter ended 31 March 2025, one of the subsidiaries Carbogen Amcis AG, had impaired expenditure incurred for capex project. The loss on account of this impairment was Rs 10.98 crore for the quarter and the year. The company's consolidated net cash from operating activities stood at Rs 375.23 crore in FY25, lower than Rs 379.43 crore in FY24. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 43.09 crore in the March 2025 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 43.09 crore in the quarter ended March 2025 as against net loss of Rs 69.92 crore during the previous quarter ended March 2024. Sales rose 9.41% to Rs 716.34 crore in the quarter ended March 2025 as against Rs 654.71 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore during the previous year ended March 2024. Sales rose 3.66% to Rs 2711.50 crore in the year ended March 2025 as against Rs 2615.77 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales716.34654.71 9 2711.502615.77 4 OPM %21.329.57 -17.2910.95 - PBDT118.5438.89 205 331.16194.74 70 PBT39.45-46.11 LP 37.42-116.12 LP NP43.09-69.92 LP 3.24-153.45 LP Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports standalone net loss of Rs 7.37 crore in the March 2025 quarter
Net Loss of Dishman Carbogen Amcis reported to Rs 7.37 crore in the quarter ended March 2025 as against net loss of Rs 31.12 crore during the previous quarter ended March 2024. Sales declined 4.64% to Rs 106.10 crore in the quarter ended March 2025 as against Rs 111.26 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 9.87 crore in the year ended March 2025 as against net loss of Rs 76.41 crore during the previous year ended March 2024. Sales rose 22.14% to Rs 399.84 crore in the year ended March 2025 as against Rs 327.35 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales106.10111.26 -5 399.84327.35 22 OPM %19.3510.40 -17.952.08 - PBDT4.69-7.51 LP 34.371.66 1970 PBT-11.41-33.63 66 -30.83-99.95 69 NP-7.37-31.12 76 -9.87-76.41 87 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 21 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dishman Carbogen Amcis' Shanghai facility clears China regulatory compliance
Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region. Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m' site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis receives affirmation in credit ratings
Dishman Carbogen Amcis has received affirmation in credit ratings from India Ratings and Research at IND A+; Stable/ IND A1+ for various debt facilities availed by the company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis allots NCDs aggregating Rs 50 cr
Dishman Carbogen Amcis has allotted 5,000 Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of face value of Rs. 1,00,000 each, aggregating to Rs 50 crore on private placement basis. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 March 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.53%, vs industry avg of 7.5%
Over the last 5 years, market share decreased from 17.14% to 13.78%
Over the last 5 years, net income has grown at a yearly rate of -54.07%, vs industry avg of 8.25%